Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel

Inclusion Criteria

• •Patient must provide written informed consent prior to participating in this protocol
• •Patient must have been prescribed TECELRA®
• •Patient's commercially manufactured product does not meet the commercial release specification
• •Repeat manufacture is not feasible or is not clinically appropriate per Investigator assessment in consultation with Adaptimmune
• •Repeat leukapheresis is not feasible or is not clinically appropriate per Investigator assessment
• •The Investigator has confirmed a favorable benefit:risk profile, following sponsor evaluation of the NC afami-cel, and deems proceeding with treatment under this EAP is in the best interest of the patient
• •Patient deemed medically fit and stable to receive NC afami-cel per Investigator assessment
• •Female patients with reproductive potential must have a negative serum or urine pregnancy test within 7 days of initiating lymphodepleting chemotherapy